We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics

58 hedge funds and large institutions have $34.2M invested in DiaMedica Therapeutics in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more call options, than puts

Call options by funds: $8K | Put options by funds: $1K

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

20% more capital invested

Capital invested by funds: $28.5M → $34.2M (+$5.7M)

2.91% more ownership

Funds ownership: 17.53%20.44% (+2.9%)

2% more funds holding

Funds holding: 5758 (+1)

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
58
Holders Change
+1
Holders Change %
+1.75%
% of All Funds
0.76%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
21
Increased
19
Reduced
5
Closed
20
Calls
$8K
Puts
$1K
Net Calls
+$7K
Net Calls Change
-$41K
Name Holding Trade Value Shares
Change
Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
$10.5K +$10.5K +2,697 New
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
$6.43K +$6.43K +1,648 New
AB
53
Amalgamated Bank
New York
$4K +$3.52K +902 New
LFA
54
Legend Financial Advisors
Pennsylvania
$3.9K +$3.9K +1,000 New
TWC
55
TD Waterhouse Canada
Ontario, Canada
$3.81K
Group One Trading
56
Group One Trading
Illinois
$472 +$472 +121 New
CPG
57
Cornerstone Planning Group
New Jersey
$359
SCM
58
Sterling Capital Management
North Carolina
$250 +$250 +64 New
Millennium Management
59
Millennium Management
New York
-$1.28M -336,880 Closed
Jane Street
60
Jane Street
New York
-$382K -100,669 Closed
HF
61
HRT Financial
New York
-$214K -56,703 Closed
Citadel Advisors
62
Citadel Advisors
Florida
-$204K -53,700 Closed
Qube Research & Technologies (QRT)
63
Qube Research & Technologies (QRT)
United Kingdom
-$140K -36,929 Closed
JG
64
Jain Global
New York
-$105K -27,679 Closed
JFG
65
Jefferies Financial Group
New York
-$98.5K -26,000 Closed
Balyasny Asset Management
66
Balyasny Asset Management
Illinois
-$95.8K -25,270 Closed
OAC
67
OMERS Administration Corp
Ontario, Canada
-$92.1K -24,300 Closed
SSA
68
Schonfeld Strategic Advisors
New York
-$62.5K -16,483 Closed
LP
69
LMR Partners
United Kingdom
-$57.5K -15,167 Closed
ECM
70
ExodusPoint Capital Management
New York
-$51K -13,343 Closed
YIH
71
Y-Intercept (HK)
Hong Kong
-$50.5K -13,335 Closed
PAS
72
Point72 Asia (Singapore)
Singapore
-$47.3K -12,480 Closed
DC
73
Diametric Capital
Massachusetts
-$47.1K -12,423 Closed
SG Americas Securities
74
SG Americas Securities
New York
-$41K -10,878 Closed
CSS
75
Cubist Systematic Strategies
Connecticut
-$12.2K -3,209 Closed

DMAC Hedge Fund Activity: Q2 2025 in Review

58 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2025, worth a combined $34.2M — up 20% from $28.5M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new DMAC positions and 20 closed out — a net gain of 1 holder — while 19 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $4.23M. The largest seller was Susquehanna International Group, cutting an estimated $2.04M.

  • 58 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2025, up from 57 in Q1 2025.
  • Funds reported $34.2M of DiaMedica Therapeutics stock for Q2 2025, up 20% quarter-over-quarter.
  • 21 funds opened new DiaMedica Therapeutics positions in Q2 2025 and 20 closed out, a net change of +1 holder.
  • The largest DiaMedica Therapeutics buyer in Q2 2025 was BlackRock, an estimated $4.23M added.
  • The largest DiaMedica Therapeutics seller in Q2 2025 was Susquehanna International Group, an estimated $2.04M sold.

Based on aggregated 13F filings for Q2 2025.